Tarsus Pharmaceuticals Q1 2024 GAAP EPS $(1.01) Beats $(1.20) Estimate, Sales $27.614M Beat $17.460M Estimate
Tarsus Pharmaceuticals Q1 2024 GAAP EPS $(1.01) Beats $(1.20) Estimate, Sales $27.614M Beat $17.460M Estimate
Tarsus Pharmaceuticals 2024年第一季度GAAP每股收益美元（1.01美元）超过预期（1.20美元），销售额2761.4万美元超过预期的174.6亿美元
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.20) by 15.83 percent. This is a 14.77 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $27.614 million which beat the analyst consensus estimate of $17.460 million by 58.16 percent. This is a 1.00K percent increase over sales of $2.500 million the same period last year.
塔苏斯制药公司（纳斯达克股票代码：TARS）公布的季度亏损为每股1.01美元，比分析师普遍预期的1.20美元（1.20美元）高出15.83％。这比去年同期每股亏损0.88美元（0.88美元）下降了14.77％。该公司公布的季度销售额为2761.4万美元，比分析师普遍预期的174.6亿美元高出58.16％。这比去年同期的25亿美元销售额增长了1.00万个百分点。